logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca

Acorda (ACOR)  stock was up around 10% reaching over $28 in premarket trading. The stock is trading now around $27 with its gains oscillating between $2 – $2.20. The enthusiasm for ACOR seems to be about rumors that  Biogen (BIIB)...

Read More

January 19, 2018

0

What happened to Sangamo yesterday?

The disease, mucopolysaccharidosis (MPS) type II, also known as the horrible Hunter syndrome is a killer with no specific treatment anywhere, except enzyme replacement therapy (ERT) that is not stopping the complications of the disease or preventing death. Sangamo (SGMO)...

Read More

September 6, 2018

0

Amgen’s Migraine Drug Passes the Trial Tests with High Grades

Amgen (AMGN) :  Phase 3b results from LIBERTY study assessing the safety and efficacy of  Aimovig™ (erenumab) 140 mg in patients with an episodic migraine who had experienced two to four previous preventive treatment failures demonstrate that the study  met...

Read More

January 23, 2018

0

ChemoCentryx’s Pancreatic Cancer Product News and Other Important Facts

ChemoCentryx (CCXI)  develops new drugs for inflammatory, autoimmune diseases and cancers. The firm’s approach comprises targeting the chemokine and chemoattractant systems with the aim of discovering, developing and commercializing orally-administered therapies for inflammation and malignancy and maybe other disease conditions. In...

Read More

January 26, 2018

0

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.

Vertex (VRTX)  announced the selection of two next-generation correctors,  VX-659  and  VX-445 , to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). The decision was based on data from...

Read More

February 1, 2018

0

Denali Therapeutics: Born with Good News in Hand.

On Dec. 12, 2017,  Denali Therapeutics (DNLI)  announced the closing of its initial public offering of 15,972,221 shares of its common stock at a price to the public of $18.00 per share. On January 5, 2018, less than one month since it...

Read More

January 5, 2018

0

CRISPR gene editing firms clear investors' confusion

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific articles that meant to caution about possible problems or by patents that were given to some Universities and denied it to others and vice...

Read More

September 12, 2018

0

Merck’s Good News. Checkpoint Inhibitors’ Revenues

Checkpoint inhibitors approved for a few firms as immunotherapy for cancer are increasingly demonstrating their superiority in extending the lives of patients when given as first-line treatments. In the news,  Merck’s (MRK)  anti-PD-1 therapy, pembrolizumab (Keytruda®) in combination with pemetrexed...

Read More

January 16, 2018

0

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

VERTEX From Europe,  Vertex (VRTX)  was informed that the European Commission has granted an extension of the Marketing Authorization for  ORKAMBI ®   (lumacaftor/ivacaftor). Orkambi is for cystic fibrosis (CF) in people with two copies of the  F508del  mutation, including...

Read More

January 11, 2018

0

AcelRx Pharmaceuticals: A small currently highlighted firm

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX) . The increased investors’ activity happened following the announcement that an Advisory Committee meeting will soon review the firm’s New Drug Application (NDA) for Dsuvia ( Sufentanil) developed...

Read More

September 14, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 42
  • 43
  • 44
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy